A Generic Drug Deal worth $83 Million
28 Aug,
2005
Ba Research International, a Houston based low-key
generic drug
Research Company founded in 1989 has received a cash
injection of $83 million from Summit Partners, a Boston
based private equity firm. The capital infusion from
Summit Partners represents the first outside investment
for Ba Research.
The deal worth $83 million ranks as one of the largest
private equity investments in a Houston firm so far
this year.
Ba Research dispenses brand-name drugs along with generic
equivalents, and then compares blood samples. The company's
Austin office analyzes the results, runs the numbers
and provides a final report.
To read more, login
http://msnbc.msn.com/id/9113679/
|
